AbbVie
ABBV
#30
Rank
NZ$496.96 B
Marketcap
$281.23
Share price
-2.74%
Change (1 day)
23.22%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

Earnings for AbbVie (ABBV)

Earnings in 2024 (TTM): NZ$11.63 Billion

According to AbbVie's latest financial reports the company's current earnings are NZ$55.00 Billion. In 2023 the company made an earning of NZ$10.65 Billion a decrease over its 2022 earnings that were of NZ$22.97 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for AbbVie from 2011 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) NZ$11.63 B9.25%
2023 NZ$10.65 B-53.62%
2022 NZ$22.97 B3.76%
2021 NZ$22.13 B282.25%
2020 NZ$5.79 B-59.67%
2019 NZ$14.36 B62.13%
2018 NZ$8.85 B-32.74%
2017 NZ$13.17 B-1.99%
2016 NZ$13.43 B18.65%
2015 NZ$11.32 B180.5%
2014 NZ$4.03 B-55.57%
2013 NZ$9.08 B-6.86%
2012 NZ$9.75 B56.05%
2011 NZ$6.25 B

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-NZ$2.07 Billion-117.15%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$11.73 Billion-197.37%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$17.30 B 43.65%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$7.97 B-33.78%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$2.62 B-78.23%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$2.23 B-81.41%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$7.10 B-40.97%๐Ÿ‡ฌ๐Ÿ‡ง UK
NZ$16.02 B 33.06%๐Ÿ‡ฌ๐Ÿ‡ง UK
NZ$1.11 B-90.71%๐Ÿ‡บ๐Ÿ‡ธ USA